评估RECIST v1.1用于预测肺转移的肉瘤患者的整体存活率
Lukas Gold1, Konstantin Klambauer1, Christian Dascalescu1
1Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
概括
固体瘤响应评估标准 (RECIST v1.1) 对于进展性疾病的标准没有准确地预测肺转移的肉瘤患者的整体存活率. 然而,新的转移的出现与更短的生存结果有显著的相关性.
科学领域:
- 在瘤学瘤学.
- 放射学 放射学是一门学科.
- 医疗成像医学成像
背景情况:
- 由于缺乏可靠的生物标志物,转移性肉瘤反应评估严重依赖成像.
- 在患有肺转移的肉瘤患者中预测整体存活率 (OS) 是具有挑战性的.
研究的目的:
- 评估响应评估标准在固体瘤 (RECIST v1.1) 在预测OS在肉瘤患者肺转移的实用性.
- 评估基于成像的进展模式及其与生存结果的相关性.
主要方法:
- 分析92名患有肺转移的肉瘤患者的CT成像.
- 肺转移的体积细分和随时间变化的评估.
- 卡普兰-梅尔生存分析以基于RECIST v1.1标准 (进展性疾病,新转移) 的OS进行比较.
主要成果:
- 在第一次随访成像时,患有进展性疾病 (PD) 的患者的生存期显著缩短 (13.9个月 vs 29.3个月).
- 在RECIST v1.1的20%单维增长值中,OS没有分层.
- 新转移的出现与显著缩短的生存期 (7.8个月与27.0个月) 相关,即使现有的病变减少,也会发生.
结论:
- 肺转移性肉瘤的成像进展模式与OS明显相关.
- 目前的RECIST v1.1标准可能需要对瘤进行特定的调整,以准确地预测存活率.
- 新转移性病变的出现是预后不佳的关键指标.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11.1K
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
789
相关概念视频
Cancer Survival Analysis
805
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
805
Kaplan-Meier Approach
662
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
662
